Investigating the effects of ETAS® on cognitive and emotional health in older adults
The Impact of Chronic Consumption of ETAS® for 12 Weeks on Cognitive, Affective, and Inflammatory Outcomes: a Randomised Parallel Group Placebo-controlled Feasibility Study
This study is testing if taking ETAS® can help older adults with mild to moderate memory problems feel better mentally and emotionally over 12 weeks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | All |
| Sponsor | University of Reading Academic / other |
| Locations | 1 site (Reading, Berkshire) |
| Trial ID | NCT06790849 on ClinicalTrials.gov |
What this trial studies
This pilot project aims to explore the chronic effects of ETAS® supplementation on cognitive, affective, and inflammatory outcomes in healthy adults aged 60-80 years who report mild to moderate cognitive complaints. The study will utilize a double-blind, randomized, placebo-controlled design, with participants assigned to receive either 300mg or 1500mg of ETAS® or a placebo for 12 weeks. Outcome measures will assess cognitive functioning, depression, anxiety, quality of life, sleep, and various inflammatory markers before and after the intervention. The goal is to determine whether ETAS® can improve mental function and overall well-being in this demographic.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
Not a fit: Patients with psychiatric or neurologic conditions, cardiometabolic diseases, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new dietary intervention to enhance cognitive and emotional health in older adults.
How similar studies have performed: While similar studies have explored cognitive interventions in older adults, the specific effects of ETAS® on this population remain novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aging between 60-80 years old * Having normal vision and hearing * Having a body mass index between 18.5 and 30 * Having mild to moderate subjective cognitive complaints Exclusion Criteria: * Smoking * Having food allergies or intolerances * Following restrictive and/or unbalanced diets * Changing dietary intake majorly in past month * Being diagnosed with any psychiatric or neurologic conditions (e.g. schizophrenia, depression, dementia) including eating disorders * Being diagnosed with any cardiometabolic diseases (including type II diabetes and cardiovascular disease), or suffering from hypertension or thrombosis related disorders or suffer from thyroid disease * Being anaemic * Currently taking anticoagulants, antiplatelet medication, antidepressants, proton-pump inhibitors * Currently consuming prebiotic or probiotic supplements * Continuous antibiotic use for \> 3 days within 1 month prior to enrolment * Continuous use of weight-loss drug for \> 1 month before screening * Having inflammatory bowel disease; coeliac disease; total colectomy or bariatric surgery; irritable bowel disease; end stage renal disease; active cancer, or treatment for any cancer, in last 3 years
Where this trial is running
Reading, Berkshire
- University of Reading, School of Psychology and Clinical Languages — Reading, Berkshire, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Piril Hepsomali, PhD
- Email: p.hepsomali@reading.ac.uk
- Phone: +44 118 378 5818
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.